284.27
price up icon0.06%   0.18
after-market Dopo l'orario di chiusura: 284.27
loading
Precedente Chiudi:
$284.09
Aprire:
$284.09
Volume 24 ore:
462.93K
Relative Volume:
0.88
Capitalizzazione di mercato:
$12.69B
Reddito:
$2.99B
Utile/perdita netta:
$1.21B
Rapporto P/E:
11.34
EPS:
25.06
Flusso di cassa netto:
$1.13B
1 W Prestazione:
-2.23%
1M Prestazione:
-9.71%
6M Prestazione:
-21.03%
1 anno Prestazione:
-10.31%
Intervallo 1D:
Value
$282.42
$287.73
Intervallo di 1 settimana:
Value
$282.00
$293.44
Portata 52W:
Value
$266.98
$417.81

United Therapeutics Corp Stock (UTHR) Company Profile

Name
Nome
United Therapeutics Corp
Name
Telefono
(301) 608-9292
Name
Indirizzo
1000 SPRING ST, SILVER SPRING, MD
Name
Dipendente
1,305
Name
Cinguettio
Name
Prossima data di guadagno
2024-10-30
Name
Ultimi documenti SEC
Name
UTHR's Discussions on Twitter

Confronta UTHR con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
284.27 12.69B 2.99B 1.21B 1.13B 25.06
Drug Manufacturers - Specialty & Generic icon
RGC
Regencell Bioscience Holdings Ltd
17.40 303.95B 0 -5.87M -767.30K -0.45
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
156.17 74.39B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.38 48.97B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.10 47.39B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.76 20.17B 16.54B -1.64B 749.00M -1.45

United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-06-02 Iniziato Cantor Fitzgerald Overweight
2025-04-25 Downgrade Wells Fargo Overweight → Equal Weight
2025-04-21 Aggiornamento BofA Securities Underperform → Neutral
2024-07-11 Downgrade Morgan Stanley Overweight → Equal-Weight
2024-02-12 Aggiornamento Goldman Sell → Neutral
2024-02-05 Iniziato Leerink Partners Outperform
2023-12-08 Iniziato Wells Fargo Overweight
2022-12-06 Iniziato UBS Buy
2022-12-05 Iniziato Goldman Sell
2022-10-11 Iniziato Morgan Stanley Overweight
2022-09-20 Reiterato BofA Securities Underperform
2022-09-19 Ripresa Wedbush Outperform
2022-02-11 Iniziato BTIG Research Neutral
2021-07-14 Aggiornamento Argus Hold → Buy
2021-04-26 Ripresa Credit Suisse Outperform
2021-02-01 Aggiornamento H.C. Wainwright Neutral → Buy
2020-09-14 Ripresa JP Morgan Overweight
2020-06-25 Reiterato H.C. Wainwright Neutral
2020-03-10 Aggiornamento Jefferies Hold → Buy
2020-02-27 Aggiornamento Cowen Market Perform → Outperform
2020-01-31 Aggiornamento JP Morgan Neutral → Overweight
2019-12-03 Iniziato BofA/Merrill Underperform
2019-08-01 Aggiornamento Jefferies Underperform → Hold
2019-08-01 Aggiornamento Ladenburg Thalmann Neutral → Buy
2019-07-01 Aggiornamento Credit Suisse Neutral → Outperform
2019-05-17 Aggiornamento UBS Sell → Neutral
2019-05-09 Aggiornamento Credit Suisse Underperform → Neutral
2018-10-12 Aggiornamento Standpoint Research Hold → Buy
2018-08-08 Downgrade Credit Suisse Neutral → Underperform
2018-04-03 Aggiornamento Credit Suisse Underperform → Neutral
2018-02-22 Reiterato Barclays Underweight
2018-01-18 Ripresa Credit Suisse Underperform
2017-12-27 Reiterato Wedbush Outperform
2017-04-27 Reiterato Wedbush Outperform
2017-03-30 Iniziato UBS Sell
2017-03-16 Iniziato Credit Suisse Underperform
Mostra tutto

United Therapeutics Corp Borsa (UTHR) Ultime notizie

pulisher
Jun 17, 2025

United Therapeutics delivers 18th consecutive quarter of topline growth - MarketScreener

Jun 17, 2025
pulisher
Jun 16, 2025

United Therapeutics EVP Paul Mahon sells $3.08m in stock By Investing.com - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

United Therapeutics Insider Sold Shares Worth $3,079,514, According to a Recent SEC Filing - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

United Therapeutics EVP Paul Mahon sells $3.08m in stock - Investing.com

Jun 16, 2025
pulisher
Jun 15, 2025

AppLovin, Chewy And Carvana Are Among Top 11 Large Cap Losers Last Week (June 9-13): Are The Others In Your Portfolio? - Benzinga

Jun 15, 2025
pulisher
Jun 11, 2025

United Therapeutics (UTHR) Maintains Neutral Rating, Price Targe - GuruFocus

Jun 11, 2025
pulisher
Jun 10, 2025

Insmed Shares Rise After Phase 2b Trial of Treprostinil Inhalation Powder in PAH Meets Endpoints - marketscreener.com

Jun 10, 2025
pulisher
Jun 10, 2025

United Therapeutics (UTHR) Stock Plummets Over 15% in Major Sell-Off - Daily Chhattisgarh News

Jun 10, 2025
pulisher
Jun 06, 2025

Treprostinil Saga Continues - JD Supra

Jun 06, 2025
pulisher
Jun 06, 2025

United Therapeutics president sells shares worth $3.7 million - MSN

Jun 06, 2025
pulisher
Jun 04, 2025

Leerink Partners maintains positive outlook on United Therapeutics stock By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 04, 2025

Leerink Partners maintains positive outlook on United Therapeutics stock - Investing.com

Jun 04, 2025
pulisher
Jun 03, 2025

United Therapeutics (NASDAQ:UTHR) Now Covered by Cantor Fitzgerald - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

United Therapeutics (UTHR) Receives New Overweight Rating from C - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Forecasting The Future: 7 Analyst Projections For United Therapeutics - Benzinga

Jun 02, 2025
pulisher
Jun 02, 2025

United Therapeutics (UTHR) Receives Overweight Rating from Canto - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

United Therapeutics (UTHR) Receives Overweight Rating from Cantor Fitzgerald | UTHR Stock News - GuruFocus

Jun 02, 2025
pulisher
May 29, 2025

Ex-United Therapeutics Exec Can't Dodge IP Suit - Law360

May 29, 2025
pulisher
May 29, 2025

United Therapeutics Co. (NASDAQ:UTHR) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World

May 29, 2025
pulisher
May 29, 2025

Those who invested in United Therapeutics (NASDAQ:UTHR) five years ago are up 151% - Yahoo

May 29, 2025
pulisher
May 27, 2025

Liquidia Scores FDA Nod For Lung Disease Drug Yutrepia, Faces Legal Challenge - Benzinga

May 27, 2025
pulisher
May 27, 2025

Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1 - Yahoo Finance

May 27, 2025
pulisher
May 26, 2025

Eisenmenger Complex Treatment Market 2032: EMA, PDMA, FDA Approvals, Medication, NICE Approvals, Clinical Trials, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight - Barchart.com

May 26, 2025
pulisher
May 24, 2025

FDA Approves Liquidia Corporation (LQDA)’s YUTREPIA Amid Patent Dispute - Insider Monkey

May 24, 2025
pulisher
May 24, 2025

Zacks Research Has Pessimistic Outlook of UTHR Q2 Earnings - Defense World

May 24, 2025
pulisher
May 23, 2025

FDA Approves Liquidia's (LQDA) Yutrepia, Court Ruling Pending - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Zacks Research Issues Negative Estimate for UTHR Earnings - Defense World

May 23, 2025
pulisher
May 21, 2025

HHS layoffs create ‘clear opportunity’ for local health, life sciences companies to add talent - The Business Journals

May 21, 2025
pulisher
May 20, 2025

Liquidia Says UTC Can’t Stop Its New Lung Drug From Launching - Bloomberg Law News

May 20, 2025
pulisher
May 15, 2025

Construction underway for new United Therapeutics facility in Stewartville - KTTC News

May 15, 2025
pulisher
May 14, 2025

Stewartville pig-to-human transplant facility to be complete in 2026 - Post Bulletin

May 14, 2025
pulisher
May 14, 2025

Interesting UTHR Put And Call Options For July 18th - Nasdaq

May 14, 2025
pulisher
May 14, 2025

Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses - Yahoo Finance

May 14, 2025
pulisher
May 13, 2025

UTHR Q1 Earnings Call: Double-Digit Growth Continues, Pipeline Expansion Remains Central - Yahoo Finance

May 13, 2025
pulisher
May 12, 2025

UTC Again Seeks To Stave Off Lung Drug Competitor In IP Suit - Law360

May 12, 2025
pulisher
May 12, 2025

Liquidia Faces Patent Litigation Filed by United Therapeutics - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

Liquidia (LQDA) Faces Patent Infringement Lawsuit from United Th - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Liquidia Says New Litigation Filed Against Co In U.S. - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics - Yahoo Finance

May 12, 2025
pulisher
May 11, 2025

Is United Therapeutics (UTHR) the Best Stock to Buy According to Jim Simons’ Renaissance Technologies? - Insider Monkey

May 11, 2025
pulisher
May 09, 2025

Liquidia Corp (LQDA) Q1 2025 Earnings Call Highlights: Strategic Advances and Legal Wins Propel ... - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

3 Big Reasons to Love United Therapeutics (UTHR) - Yahoo Finance

May 09, 2025
pulisher
May 08, 2025

MANNKIND CORP SEC 10-Q Report - TradingView

May 08, 2025
pulisher
May 08, 2025

Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update - Yahoo Finance

May 08, 2025
pulisher
May 07, 2025

TD Cowen maintains United Therapeutics stock Buy rating By Investing.com - Investing.com Nigeria

May 07, 2025
pulisher
May 07, 2025

TD Cowen maintains United Therapeutics stock Buy rating - Investing.com

May 07, 2025
pulisher
May 07, 2025

3 Market-Beating Stocks with Solid Fundamentals - Yahoo Finance

May 07, 2025
pulisher
May 06, 2025

United Therapeutics (UTHR) Target Price Lowered by Argus, Retains Buy Rating | UTHR Stock News - GuruFocus

May 06, 2025
pulisher
May 05, 2025

Liquidia Fends Off Indication Challenge In UTC Tyvaso Fight - Law360

May 05, 2025
pulisher
May 05, 2025

United Therapeutics (UTHR) Receives Reiterated "Buy" Rating from HC Wainwright | UTHR Stock News - GuruFocus

May 05, 2025

United Therapeutics Corp Azioni (UTHR) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

United Therapeutics Corp Azioni (UTHR) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Mesa Nilda
Director
Jun 24 '25
Sale
289.99
645
187,045
4,883
Giltner Richard
Director
Jun 24 '25
Option Exercise
175.43
5,000
877,150
22,420
Giltner Richard
Director
Jun 24 '25
Sale
289.60
3,036
879,214
19,384
$125.42
price down icon 1.02%
drug_manufacturers_specialty_generic RDY
$15.07
price down icon 1.70%
$9.01
price down icon 1.21%
$14.29
price down icon 0.07%
$16.76
price up icon 1.21%
Capitalizzazione:     |  Volume (24 ore):